Shanghai RAAS(SZ:002252) Shang Hai Zheng Quan Bao·2025-10-28 23:15Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has completed its share repurchase plan, acquiring a total of 69,081,952 shares, which represents 1.04% of the company's total share capital, with a total expenditure of approximately RMB 474.94 million [4][6]. Summary by Sections Share Repurchase Plan - The company approved a share repurchase plan on January 13, 2025, with a total budget between RMB 250 million and RMB 500 million, and a maximum repurchase price of RMB 9.55 per share [2][3]. - The repurchase period is set for 12 months from the approval date, with the possibility of early completion if certain conditions are met [2]. Implementation Details - The repurchase was executed from April 2, 2025, to October 28, 2025, through a centralized bidding method [4]. - The highest transaction price was RMB 7.09 per share, and the lowest was RMB 6.62 per share [4]. Compliance and Impact - The repurchase was conducted in accordance with relevant regulations, and the execution details aligned with the approved plan [5][12]. - The completion of the repurchase is not expected to significantly impact the company's financials, operations, or debt obligations, nor will it alter the company's control status [6]. Future Arrangements - The repurchased shares will be used for employee stock ownership plans or equity incentives, with no immediate changes to the total share capital [14]. - If the shares are not utilized within 12 months, they will be canceled, leading to a reduction in registered capital [15].